Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,721 to 1,740 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Gene signature of m6A RNA regulators in diagnosis, prognosis, treatment, and immune microenvironment for cervical cancer. | Sci Rep | 2022 | 36271283 | PubTator, text mining | PubMed |
| Small-Molecule Ebselen Binds to YTHDF Proteins Interfering with the Recognition of N 6-Methyladenosine-Modified RNAs. | ACS Pharmacol Transl Sci | 2022 | 36268123 | PubTator, text mining | PubMed |
| An Analysis of BMP1 Associated with m6A Modification and Immune Infiltration in Pancancer. | Dis Markers | 2022 | 36267461 | PubTator, text mining | PubMed |
| Identification and verification of IGFBP3 and YTHDC1 as biomarkers associated with immune infiltration and mitophagy in hypertrophic cardiomyopathy. | Front Genet | 2022 | 36267414 | PubTator, text mining | PubMed |
| Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities. | Cancer Commun (Lond) | 2022 | 36266736 | PubTator, text mining | PubMed |
| New insights into the epitranscriptomic control of pluripotent stem cell fate. | Exp Mol Med | 2022 | 36266446 | PubTator, text mining | PubMed |
| The emerging importance of METTL5-mediated ribosomal RNA methylation. | Exp Mol Med | 2022 | 36266443 | PubTator, text mining | PubMed |
| METTL14 promotes migration and invasion of choroidal melanoma by targeting RUNX2 mRNA via m6A modification. | J Cell Mol Med | 2022 | 36264762 | PubTator, text mining | PubMed |
| Novel insight into the functions of N6‑methyladenosine modified lncRNAs in cancers (Review). | Int J Oncol | 2022 | 36263625 | PubTator, text mining | PubMed |
| FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. | Int J Biol Sci | 2022 | 36263177 | PubTator, text mining | PubMed |
| The m6A-methylated mRNA pattern and the activation of the Wnt signaling pathway under the hyper-m6A-modifying condition in the keloid. | Front Cell Dev Biol | 2022 | 36263010 | PubTator, text mining | PubMed |
| Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer. | BMC Bioinformatics | 2022 | 36261786 | PubTator, text mining | PubMed |
| LCAT1 is an oncogenic LncRNA by stabilizing the IGF2BP2-CDC6 axis. | Cell Death Dis | 2022 | 36257938 | PubTator, text mining | PubMed |
| Natural antisense transcripts as drug targets. | Front Mol Biosci | 2022 | 36250017 | PubTator, text mining | PubMed |
| Transcriptome-wide m6A methylome analysis uncovered the changes of m6A modification in oral pre-malignant cells compared with normal oral epithelial cells. | Front Oncol | 2022 | 36249071 | PubTator, text mining | PubMed |
| m6A-binding protein IGF2BP1 promotes the malignant phenotypes of lung adenocarcinoma. | Front Oncol | 2022 | 36249006 | PubTator, text mining | PubMed |
| GPI: An indicator for immune infiltrates and prognosis of human breast cancer from a comprehensive analysis. | Front Endocrinol (Lausanne) | 2022 | 36246907 | PubTator, text mining | PubMed |
| Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients. | Front Genet | 2022 | 36246627 | PubTator, text mining | PubMed |
| Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. | Front Genet | 2022 | 36246622 | PubTator, text mining | PubMed |
| Crosstalk among N6-methyladenosine modification and RNAs in central nervous system injuries. | Front Cell Neurosci | 2022 | 36246528 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=87